In the article by Gibson et al, “Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy,” which published in the January 24, 2017, issue of the journal (Circulation. 2017;135:323–333. DOI: 10.1161/CIRCULATIONAHA.116.025783), several corrections are needed. In Figure 2, as well as in the figure legends for Figures 1– 4, the dose of rivaroxaban was incorrectly listed as 2.4 mg. The correct dosage is 2.5 mg.
The correction has been made to the current online version of the article, which is available at http://circ.ahajournals.org/content/135/4/323.
Footnotes
Circulation is available at http://circ.ahajournals.org.